Our study strongly suggests that BM is an independent predictor of poor prognosis for NSCLC patients with EGFR mutations receiving EGFR-TKIs, which may be attributed to a decline in peripheral lymphocytes. Here, EGFR is linked to non-small cell lung carcinoma.